| Literature DB >> 24210217 |
Atsushi Inagaki1, Emi Tajima, Miyuki Uranishi, Haruhito Totani, Yu Asao, Hiroka Ogura, Ayako Masaki, Tatsuya Yoshida, Fumiko Mori, Asahi Ito, Hiroki Yano, Masaki Ri, Satoshi Kayukawa, Takae Kataoka, Shigeru Kusumoto, Takashi Ishida, Yoshihito Hayami, Ichiro Hanamura, Hirokazu Komatsu, Hiroshi Inagaki, Yasufumi Matsuda, Ryuzo Ueda, Shinsuke Iida.
Abstract
CCND1, FGFR3 and c-MAF mRNA expression of tumor samples from 123 multiple myeloma patients were analyzed by global RQ/RT-PCR. CCND1, FGFR3 and c-MAF were positive in 44 (36%), 28 (23%) and 16 (13%) of patients, respectively. In 7 patients, both FGFR3 and c-MAF were positive. The expression of c-MAF was independent unfavorable prognostic factors for overall survival (OS). Autologous stem cell transplantation improved progression-free survival of CCND1-positive patients. Bortezomib, thalidomide or lenalidomide extended OS of FGFR3 and/or c-MAF-positive patients. Thus, CCND1, FGFR3 and c-MAF mRNA expression can predict survival and is useful for planning stratified treatment strategies for myeloma patients.Entities:
Keywords: C-MAF; CCND1; FGFR3; FISH; Multiple myeloma; PCR; Survival
Mesh：
Substances：
Year: 2013 PMID： 24210217 DOI： 10.1016/j.leukres.2013.09.026
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156